Evotec
Joseph Van Tiem has extensive work experience in the finance and accounting field. Joseph is currently serving as the Executive Vice President and Head of Global Accounting and Reporting at Evotec. Prior to this, they worked at Razor Group as the VP Finance and Head of Finance and Accounting. Joseph also held the position of Senior Manager Group Accounting at NEW WORK SE. Joseph has experience as the Global Head of Accounting at Dreamlines GmbH and as the Head of Accounting Operations at Marley Spoon. Joseph began their career at PwC Deutschland, where they worked as a Manager and Senior Consultant. Joseph also worked at PwC as a Core Assurance Senior Associate and Risk Assurance Associate.
Joseph Van Tiem completed their Bachelor of Science (B.S.) in Accounting from Oakland University from 2010 to 2012. Prior to that, they studied Accounting at Xavier University from 2006 to 2009 without obtaining a degree. Joseph also holds a certification as a Certified Public Accountant from the State of Michigan, although the specific details of when and where they obtained it are not provided.
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.